Drug Profile
Research programme: HIV infection therapeutics - ViroChem Pharma
Alternative Names: CCR5 receptor antagonists - ViroChem Pharma; HIV maturation inhibitors - ViroChem PharmaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ViroChem Pharma
- Developer Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action CCR5 receptor antagonists; HIV integrase inhibitors; Nucleocapsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Canada (PO)
- 12 Mar 2009 ViroChem Pharma has been acquired and merged into Vertex Pharmaceuticals
- 12 Mar 2009 ViroChem Pharma has been acquired by Vertex Pharmaceuticals